Tech Center 1600 • Art Units: 1643 1644
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18253425 | ADMINISTRATION OF STING AGONIST, CHECKPOINT INHIBITORS, AND RADIATION | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18260377 | ANTI-CD72 NANOBODIES FOR IMMUNOTHERAPY | Non-Final OA | The Regents of the University of California |
| 17613881 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | Final Rejection | The Regents of the University of California |
| 17817925 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Non-Final OA | Hoffmann-La Roche Inc. |
| 18349012 | METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R ANTAGONIST | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 17615732 | MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 17611073 | COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18008535 | MATERIALS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | Non-Final OA | University of Florida Research Foundation, Inc. |
| 17529574 | Compositions and Methods for Treating Late Stage Lung Cancer | Non-Final OA | AstraZeneca AB |
| 17814811 | SPLIT CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | Final Rejection | Kite Pharma, Inc. |
| 18476345 | PHARMACEUTICAL COMPOSITION COMPRISING TOLL-LIKE RECEPTOR AGONIST AND STIMULATOR OF INTERFERON GENES AGONIST AND USE THEREOF | Non-Final OA | National Health Research Institutes |
| 18175796 | MULTISPECIFIC ANTIBODIES AND USES THEREOF | Non-Final OA | Pfizer Inc. |
| 17802794 | ANTIGEN-PRESENTING EXTRACELLULAR VESICLES, COMPOSITION CONTAINING SAME, AND METHOD FOR PRODUCTION THEREOF | Non-Final OA | NISSAN CHEMICAL CORPORATION |
| 17913072 | ANTI-TN-MUC1 CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED |
| 18007468 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | Non-Final OA | CureVac SE |
| 18282322 | ANTI-ALPP/ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | Non-Final OA | SEAGEN INC. |
| 17698617 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | Non-Final OA | The Brigham and Women`s Hospital, Inc. |
| 18253721 | ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY | Non-Final OA | A2 Biotherapeutics, Inc. |
| 17312317 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | Final Rejection | The University of Western Australia |
| 18043574 | COMPOSITIONS AND METHODS TO TARGET ANTI-RH ANTIBODY | Non-Final OA | PORTON ADVANCED SOLUTIONS LTD. |
| 17915837 | EPITOPE REGION-BRIDGING BIPARATOPIC ANTIBODY AND METHOD FOR PRODUCING SAME | Non-Final OA | NATIONAL INSTITUTES OF BIOMEDICAL INOVATION, HEALTH AND NUTRITON |
| 17782129 | METHODS FOR EXPANDING GAMMA DELTA T-CELL POPULATIONS WITH MULTIVALENT AGENTS AND COMPOSITIONS THEREOF | Non-Final OA | ADICET THERAPEUTICS, INC. |
| 17605061 | MEANS AND METHODS FOR TREATING BURKITT LYMPHOMA OR LEUKEMIA | Final Rejection | AMGEN RESEARCH (MUNICH) GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy